NPI-002 Intravitreal Implant for the Delay of Cataract Progression

Last updated: November 12, 2024
Sponsor: Nacuity Pharmaceuticals, Inc.
Overall Status: Active - Recruiting

Phase

1/2

Condition

Vision Loss

Eye Disorders/infections

Eye Disease

Treatment

NPI-002 Intravitreal Implant

Clinical Study ID

NCT05026632
C-21-01
  • Ages > 18
  • All Genders

Study Summary

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Indicated for vitrectomy

  2. Natural Lens in place at time of vitrectomy

  3. Some cataract present as assessed pre-operatively

Exclusion

Exclusion Criteria:

  1. Previous intraocular surgery in study eye.

  2. Clear zonular weakness or defects / coloboma.

  3. Not on stable dose of medications for other conditions.

  4. Need for oral corticosteroids during study participation.

  5. Evidence or history of uveitis, or ocular ischemia.

  6. Current smoker

  7. Use of supplemental oxygen

  8. Evidence or history of proliferative diabetic retinopathy.

  9. Current lung disease (PU, COPD, Asthma) resulting in decreased oxygen saturation.

  10. Sensitivity to thiol compounds.

  11. Participation in another clinical trial.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: NPI-002 Intravitreal Implant
Phase: 1/2
Study Start date:
January 27, 2022
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Royal Adelaide Hospital

    Adelaide,
    Australia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.